Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement
- PMID: 18678845
- DOI: 10.7326/0003-4819-149-3-200808050-00008
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement
Abstract
Description: Update of the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation statement about screening for prostate cancer.
Methods: The USPSTF evaluated randomized, controlled trials of the benefits of prostate cancer screening; cohort and cross-sectional studies of the psychological harms of false-positive prostate-specific antigen test results; and evidence on the natural history of prostate-specific antigen-detected prostate cancer to address previously identified gaps in the evidence from the 2002 USPSTF recommendation.
Recommendations: Current evidence is insufficient to assess the balance of benefits and harms of screening for prostate cancer in men younger than age 75 years (I statement). Do not screen for prostate cancer in men age 75 years or older (Grade D recommendation).
Comment in
-
Should you screen men >or= 75 years of age for prostate cancer?J Fam Pract. 2008 Nov;57(11):710. J Fam Pract. 2008. PMID: 19023902 No abstract available.
-
Are age-based criteria the best way to determine eligibility for prostate cancer screening?Ann Intern Med. 2009 Feb 3;150(3):220-1; author reply 221-2. doi: 10.7326/0003-4819-150-3-200902030-00018. Ann Intern Med. 2009. PMID: 19189916 No abstract available.
-
Are age-based criteria the best way to determine eligibility for prostate cancer screening?Ann Intern Med. 2009 Feb 3;150(3):221; author reply 221-2. doi: 10.7326/0003-4819-150-3-200902030-00019. Ann Intern Med. 2009. PMID: 19189918 No abstract available.
Summary for patients in
-
Summaries for patients. Screening for prostate cancer with prostate-specific antigen testing: U.S. Preventive Services Task Force recommendations.Ann Intern Med. 2008 Aug 5;149(3):I37. doi: 10.7326/0003-4819-149-3-200808050-00002. Ann Intern Med. 2008. PMID: 18678840 No abstract available.
Similar articles
-
Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.Ann Intern Med. 2008 Aug 5;149(3):192-9. doi: 10.7326/0003-4819-149-3-200808050-00009. Ann Intern Med. 2008. PMID: 18678846 Review.
-
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710. JAMA. 2018. PMID: 29801017
-
Summaries for patients. Screening for prostate cancer with prostate-specific antigen testing: U.S. Preventive Services Task Force recommendations.Ann Intern Med. 2008 Aug 5;149(3):I37. doi: 10.7326/0003-4819-149-3-200808050-00002. Ann Intern Med. 2008. PMID: 18678840 No abstract available.
-
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.Ann Intern Med. 2012 Jul 17;157(2):120-34. doi: 10.7326/0003-4819-157-2-201207170-00459. Ann Intern Med. 2012. PMID: 22801674
-
Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Aug. Report No.: 08-05121-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Aug. Report No.: 08-05121-EF-1. PMID: 20722160 Free Books & Documents. Review.
Cited by
-
The Short- and Long-Term Anticipation of Prostate Cancer Incidence in Korea: Based on Social Aging Trends and Prostate-Specific Antigen Testing Rate during the Last Decade.Cancers (Basel). 2024 Jan 24;16(3):503. doi: 10.3390/cancers16030503. Cancers (Basel). 2024. PMID: 38339255 Free PMC article.
-
A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer.PLoS One. 2024 Feb 8;19(2):e0285745. doi: 10.1371/journal.pone.0285745. eCollection 2024. PLoS One. 2024. PMID: 38329970 Free PMC article.
-
Trends in prostate cancer incidence among Black men in the Caribbean and the United States.Prostate. 2023 Sep;83(12):1207-1216. doi: 10.1002/pros.24580. Epub 2023 May 27. Prostate. 2023. PMID: 37244749 Free PMC article.
-
Recent Trends in Biosensing and Diagnostic Methods for Novel Cancer Biomarkers.Biosensors (Basel). 2023 Mar 18;13(3):398. doi: 10.3390/bios13030398. Biosensors (Basel). 2023. PMID: 36979610 Free PMC article. Review.
-
Trends of stratified prostate cancer risk in a single Korean province from 2003 to 2021: A multicenter study conducted using regional training hospital data.Investig Clin Urol. 2023 Mar;64(2):140-147. doi: 10.4111/icu.20220317. Investig Clin Urol. 2023. PMID: 36882172 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical